MitoQ Enhances CYP19A1 Expression to Stimulate WNT/β-Catenin Signaling Pathway for Promoting Hair Growth in Androgenetic Alopecia

This study demonstrates that MitoQ can alleviate symptoms of androgenetic alopecia (AGA) by targeting mitochondrial dysfunction and enhancing CYP19A1 expression, which regulates the WNT/β-catenin signaling pathway. In a mouse model of DHT-induced hair loss, MitoQ was shown to reverse hair growth reduction and mitigate apoptosis caused by decreased CYP19A1 expression. Network pharmacology identified 75 drug targets and 367 disease targets, highlighting MitoQ's potential in hormonal response and transcriptional regulation pathways. These findings suggest that MitoQ could be a promising therapeutic intervention for AGA, with CYP19A1 as a valuable target.